As of August 2010, Latisse was the only prescription medication approved by the Food and Drug Administration for the treatment of thin eyelashes. Other products may condition or enhance the appearance of eyelashes, but Latisse is the only...
Colorblindess, also referred to as color vision defiency, can be caused by a number of factors. This condition can be genetically inherited, induced by exposure to certain environmental toxins or occur as a side effect from certain medications....
The first eyelash growth treatment backed by scientific study and clinical trials was approved by the U.S. Food & Drug Administration in December 2008. The active ingredient used by Allergan, bimatoprost, is featured in the topical eyelash...
Latisse is an ophthalmic solution containing the active ingredient bimatoprost. Its manufacturer Allergan originally produced bimatoprost as the brand Lumigan for treating glaucoma. This product turned out to have a positive side effect, as it...
